Sacchi S, Kantarjian HM, O'Brien SM, Cortes JE, Kornblau SM , Keating MJ, Freireich EJ, Talpaz M
To date, incretin-based approaches for obesity management appear as the most promising and rapidly developing (Supplementary Table 1), with innovations such as once-weekly (OW) injectable triple GIPR/GCGR/GLP-1R agonist retatrutide (LY3437943), cagrilintide (long-acting amylin analogue)/semaglutide 2.4 mg (CagriSema) combination, GCGR/GLP-1R dual agonists, high-dose oral semaglutide, and oral non-peptide GLP-1 receptor agonist orforglipron, with relevant implications in terms of patients compliance and environmental sustainability
& Reichenbaugh, S
Retatrutide reconstitution ratios Retatrutide is investigational not FDA-approved for any indication and trial protocols rather than vendor prescribing information are the documented source for reconstitution ratios
10.3390/s17091990
Given the short half-life, twice-daily dosing provides additional exposure compared to once-daily protocols at the same total dose